durvalumab
Selected indexed studies
- Durvalumab Plus Carboplatin/Paclitaxel Followed by Maintenance Durvalumab With or Without Olaparib as First-Line Treatment for Advanced Endometrial Cancer: The Phase III DUO-E Trial. (J Clin Oncol, 2024) [PMID:37864337]
- Tremelimumab plus Durvalumab in Unresectable Hepatocellular Carcinoma. (NEJM Evid, 2022) [PMID:38319892]
- Perioperative Durvalumab with Neoadjuvant Chemotherapy in Operable Bladder Cancer. (N Engl J Med, 2024) [PMID:39282910]
_Worker-drafted node — pending editorial review._
Connections
No connections recorded yet.
Sources
- Durvalumab Plus Carboplatin/Paclitaxel Followed by Maintenance Durvalumab With or Without Olaparib as First-Line Treatment for Advanced Endometrial Cancer: The Phase III DUO-E Trial. (2024) pubmed
- Tremelimumab plus Durvalumab in Unresectable Hepatocellular Carcinoma. (2022) pubmed
- Perioperative Durvalumab with Neoadjuvant Chemotherapy in Operable Bladder Cancer. (2024) pubmed
- Durvalumab plus platinum-etoposide versus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial. (2019) pubmed
- Durvalumab plus Gemcitabine and Cisplatin in Advanced Biliary Tract Cancer. (2022) pubmed
- MATTERHORN: phase III study of durvalumab plus FLOT chemotherapy in resectable gastric/gastroesophageal junction cancer. (2022) pubmed
- Durvalumab With or Without Tremelimumab in Combination With Chemotherapy as First-Line Therapy for Metastatic Non-Small-Cell Lung Cancer: The Phase III POSEIDON Study. (2023) pubmed
- Durvalumab, with or without tremelimumab, plus platinum-etoposide versus platinum-etoposide alone in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): updated results from a randomised, controlled, open-label, phase 3 trial. (2021) pubmed
- Durvalumab plus gemcitabine and cisplatin in advanced biliary tract cancer (TOPAZ-1): patient-reported outcomes from a randomised, double-blind, placebo-controlled, phase 3 trial. (2024) pubmed
- Durvalumab versus placebo with chemoradiotherapy for locally advanced cervical cancer (CALLA): a randomised, double-blind, phase 3 trial. (2023) pubmed